Monitoring the Hemodialysis Dose



Similar documents
Hemodialysis Dose and Adequacy

Organization and Structure of a Peritoneal Dialysis Program: an important ingredient for success

Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, ESRD Registry Committee, Korean Society of Nephrology*

Bundling and the QIP. Jay B. Wish, MD NKF of Illinois 15 th Annual Interdisciplinary Nephrology Conference October 24, 2014

survival, morality, & causes of death Chapter Nine introduction 152 mortality in high- & low-risk patients 154 predictors of mortality 156

Peritoneal Dialysis Adequacy. Suzanne Watnick, MD Associate Professor of Medicine Training Program Director Oregon Health & Science University

Nierfunctiemeting en follow-up van chronisch nierlijden

Diabetic Nephropathy

VKA in Dialysis: Navigating between Scylla and Charybdis. An De Vriese Nephrology & Infectious Diseases AZ Sint-Jan Brugge

What You Should Know About Dialyzer Reuse A Guide for Hemodialysis Patients and their Families

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2005

Models of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK

Haemodialysis. Dialysers and Filters Product Range

Home Dialysis Benchmarks Workgroup. Peritoneal Dialysis (PD)

Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV

The Dialog+ Dialysis System

KDIGO THE GEORGE INSTITUTE FOR GLOBAL HEALTH. Antiocoagulation in diabetes and CKD Vlado Perkovic

Continuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS

NUTRITIONAL REQUIREMENTS OF PERITONEAL DIALYSIS. J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital

Hemodialysis remains the major modality of renal replacement

Haemodialysis Blood Results

Clinical Performance Goals

Advantages and disadvantages of CRRT in ARF patients. Norbert Lameire Renal Division University Hospital Ghent, Belgium

Low diabetes numeracy predicts worse glycemic control

Regeneration of Hemodialyzers with Ozone

Guide to the Quarterly Dialysis Facility Compare Preview for April 2016 Report: Overview, Methodology, and Interpretation

Hemodialysis: What You Need to Know

Population health management at Cleveland clinic

Tunneled Hemodialysis Catheters: Placement and complications

The sooner the better

Albuminuria versus GFR as markers of diabetic CKD progression

PRISMAFLEX CRRT SYSTEM

Peritoneal Dialysis Prescription and Modalities

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

DIALYSIS COMPACT. The function, diseases and treatments for the human kidney.

Renal rescue for myeloma patients

Chronic Kidney Disease (CKD) Program

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using

Cirrhosis and HCV. Jonathan Israel M.D.

Elderly Diabetic Patients on Peritoneal Dialysis

MANAGEMENT OF LIVER CIRRHOSIS

CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

EMODIALISI NOTTURNA. dr.ssa Patrizia Ondei. U.O. Nefrologia e Dialisi. A.O. Papa Giovanni XXIII Bergamo

Kidney Disease WHAT IS KIDNEY DISEASE? TESTS TO DETECT OR DIAGNOSE KIDNEY DISEASE TREATMENT STRATEGIES FOR KIDNEY DISEASE

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

Understanding Treatment Options for Renal Therapy

Managing End-Stage Renal Disease Improving clinical outcomes and reducing the cost of care for Medicare Advantage, Medicaid and Commercial Populations

Estimated GFR Based on Creatinine and Cystatin C

Choosing A Treatment For Kidney Failure

20/03/2013. What is it and how did it disappear? What is it and how did it not disappear?

Robert Okwemba, BSPHS, Pharm.D Philadelphia College of Pharmacy

Hemodialysis catheter infection

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

David Axelrod, MD, MBA. Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center

High Blood Pressure and Chronic Kidney Disease

Update in Contrast Induced Nephropathy

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Inpatient consultation service. Renal Transplantation Service

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.

Sustained Low Efficient Dialysis

Xarelto (Rivaroxaban)

William B. Smith, MD President. Patrick R. Ayd, RN, MBA Chief Operating Officer. SNBL-CPC Baltimore, Maryland

High Blood pressure and chronic kidney disease

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

TECHNICAL/CLINICAL TOOLS BEST PRACTICE 7: Depression Screening and Management

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Peritoneal dialysis all you need to know about your blood results

Care of an End Stage Renal Disease Patient. December 2012

Prognostic impact of uric acid in patients with stable coronary artery disease

Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure

November 15, Ann Laramee MS ANP-BC ACNS-BC CHFN FletcherAllen.org

Assessment of Dietary Management of Patient during Dialysis

Roux-en-Y Gastric Bypass

American Kidney Fund 6110 Executive Boulevard Suite 1010 Rockville, Maryland 20852

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

The author has no disclosures

Transcription:

KDIGO Controversies Conference Novel techniques and innovation in blood purification: How can we improve clinical outcomes in hemodialysis? October 14-15, 2011 Paris France Monitoring the Hemodialysis Dose Tom Depner, M.D. University of California, Davis

Slide 2 2001 By Default! Removal of accumulated small solutes is important A Free sample background from www.pptbackgrounds.fsnet.co.uk

How long will I live if I choose to stop dialysis? This varies from person to person. People who stop dialysis may live anywhere from one week to several weeks, depending on the amount of kidney function they have left and their overall medical condition. National Kidney Foundation web site

Art Buchwald Famous as a syndicated humorist in life, after his death he is more notable for his reputation as the man who beat hospice and the kidney machine.

How long will I live if I choose to stop dialysis? The median time to death after stopping dialysis in a series of 18 patients reported by Rich was 7 days (0-17 days) Rich A, Palliative Med 15:513-14, 2001.

The cause of death is uremia Principal cause: accumulation of toxic solutes normally excreted by the kidney Evidence: dialysis works by removing small solutes. Death is not due to anemia, vitamin D deficiency, hyperparathyroidism, fluid overload, accumulation of beta 2- microglobulin, etc, etc.

Minimum urea clearance for Hemodialysis KDOQI guidelines call for a continuous equivalent Kt/V urea of 2.0 volumes/week. 2.0 volumes per week x 35 L = 70 L/week = 70,000 ml/l /10080 min/week = 7 ml/min

Slide 8 HEMO Study: Survival by Kt/V Group 2001 By Default! A Free sample background from www.pptbackgrounds.fsnet.co.uk Eknoyan et al, N Eng J Med 2002

Weekly Dialysis Dose (stdkt/v) 7 6 5 4 3 2 1 Effect of Increasing Number of Dialysis Sessions Per Week Daily Dialysis HEMO: Standard 0 0.0 0.5 1.0 1.5 Dialysis dose each dialysis (ekt/v) 6 3 Hemodialysis sessions/wk HEMO: High 7 ml/min 8 ml/min 9

Slide 10 Deficiencies of Kt/V Residual kidney function not considered Solute disequilibrium is under-represented No provision for dialysis frequency K and t may not be equivalent V is independently associated with outcome Non-linear correlation with outcome

Effect of K r -urea on mortality in HD patients Termorshuizen F, et al: JASN 15:1061-70, 2004 RR mortality 20 18 16 14 12 10 8 6 5.0 to 62.6 Adjustments: age, comorbidity score, primary kidney disease, SGA, BMI 4 1.1 to 2.6 reference 2 0 0 0 to 0.84 >0.84 K r T/V per week

Slide 12 Deficiencies of Kt/V Residual kidney function not considered Solute disequilibrium is under-represented No provision for dialysis frequency K and t may not be equivalent V is independently associated with outcome Non-linear correlation with outcome

Slide 15 Standard K (and Kt/V) - Gotch Standard K = continuous removal rate average peak concentration In a steady state, the removal rate is equal to the generation rate (G) Standard K = G average peak concentration

Slide 16 2001 By Default! Standard Kt/V 10080 stdkt/v = 1 e ekt/v ekt/v 1 e ekt/v t 10080 + Nt 1 A Free sample background from www.pptbackgrounds.fsnet.co.uk Gotch, FA: Nephrol Dial Transplant 13 Suppl 6:10-14, 1998 Leypoldt, JK: Seminars In Dialysis 17:142-145, 2004

Slide 17 2001 By Default! Standard Kt/V adjusted for Uf and Kru stdkt/v = S/[1 - (0.74/F) Uf/V] + Kru [0.974/(spKt/V + 1.62) + 0.4] 10/V S is the unadjusted stdkt/v per week F is the number of dialyses/week Uf is the weekly fluid removal in liters Kru is the residual native kidney clearance of urea in ml/min spkt/v is the single pool Kt/V per dialysis V is the urea distribution volume in liters A Free sample background from www.pptbackgrounds.fsnet.co.uk Daugirdas J, et al: Kidney Int 2010

Standard Kt/V per week Continuous vs. intermittent clearance expressions 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.00 0.50 1.00 1.50 2.00 2.50 spkt/v per dialysis 7/week 6 5 4 3 2 1

Slide 19 Re-defined Kt/V (per week) 7.0 6.0 5.0 4.0 2001 By Default! Continuous versus peak concentration methods 3.0 2.0 1.0 A Free sample background from www.pptbackgrounds.fsnet.co.uk Mean method Peak method 0.0 0.00 0.50 1.00 1.50 2.00 2.50 spkt/v per dialysis 7/week 6 5 4 3 2 1

Slide 20 Deficiencies of Kt/V Residual kidney function not considered Solute disequilibrium is under-represented No provision for dialysis frequency K and t may not be equivalent V is independently associated with outcome Non-linear correlation with outcome

Slide 21 1.20 Effect of treatment time on ekt/v spkt/v 2001 By Default! Kt/V 1.10 1.00 0.90 0.80 0.70 0.60 1.09 0.87 ekt/v A Free sample background from www.pptbackgrounds.fsnet.co.uk 2 4 6 8 10 T d (treatment time in hours)

Treatment time predicts mortality Saran et al from DOPPS, Kid Int 69:1222-28, 2006 New NKF-KDOQI Hemodialysis Guidelines

Slide 23 Relative Risk of death adjusted for age, sex, race & other factors 1.40 1.20 1.00 0.80 Mortality and Body Mass Index USRDS: 3607 patients enrolled in CMAS, Jan 1991 Source: Leavey et al, AJKD 31:1002, 1998 A Free sample background from www.pptbackgrounds.fsnet.co.uk quintile means ñ 95% confidence intervals 15 20 25 30 35 40 45 BMI 2001 By Default!

Slide 24 2001 By Default! K urea t urea V urea A Free sample background from www.pptbackgrounds.fsnet.co.uk

Slide 25 2001 By Default! 43,334 patients Continuous risk (hazard) plane for Kt and BSA. The analysis did not include an interaction term between Kt and BSA and was case mix adjusted. Continuous risk (hazard) plane for Kt and BSA. The analysis included an interaction term between Kt and BMI and was case mix adjusted. Lowrie E, et al: KI 62:1891-7, 2002 A Free sample background from www.pptbackgrounds.fsnet.co.uk

Slide 26 Deficiencies of Kt/V Residual kidney function not considered Solute disequilibrium is under-represented No provision for dialysis frequency K and t may not be equivalent V is independently associated with outcome Non-linear correlation with outcome

Concentration (Dose) - Response Curve Hill equation: applies to a direct reversible effect 1.0 Response (R) 0.8 0.6 0.4 0.2 R = C S (1/Q) + C S 0.0 0.5 1.0 10.0 Concentration (C in arbitrary units)

Concentration versus Clearance 10.0 8.0 6.0 C = 1/K 4.0 2.0 0.0 0.0 0.2 0.4 0.6 0.8 1.0 Clearance (K) in arbitrary units) Concentration (C in arbitrary units)

5 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 0 5 10 15 20 Steady-state solute concentration

Some proposed improvements to Kt/V Include residual native kidney clearance (Kr) Account for solute disequilibrium» ekt/v Allow for more frequent dialysis» Standardized Kt/V Index to surface area instead of V Tighter correlation with outcome» reciprocal of Kt/V

Slide 31 Summary: uremia is a complex state 2001 By Default! Comorbidity (DM, CVD, nutrition, anemia, etc) Residual Syndrome: Slowly accumulating solutes: B2-microglobulin & other peptides Calcium & phosphate deposits Protein-bound toxins? AGE s? Carbamylated proteins? Toxic effect of dialysis - exposure to membrane, hemodynamic effects A Free sample background from www.pptbackgrounds.fsnet.co.uk Life threatening toxins

Slide 32 2001 By Default! Future of dose monitoring Because control of small solute concentrations must be the principal goal of replacement therapy, future efforts should focus not on whether we should measure small solute clearance, but what else we should measure and do for our patients. A Free sample background from www.pptbackgrounds.fsnet.co.uk

Adequacy of Dialysis = Removal of Toxins = Prevention of Uremia = Restoration of Health